Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed ...
Tag: nsclc
#VisualAbstract: Perioperative Toripalimab Plus Chemotherapy Improves Event-Free Survival in Patients With Resectable Non–Small-Cell Lung Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Amivantamab plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions Showed Superior Progression-Free Survival Than Chemotherapy Alone
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
#VisualAbstract: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive Non-Small Cell Lung Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
Immunotherapy plus stereotactic radiotherapy improves outcomes in early-stage lung cancer
1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR ...
Tumor Treating Fields vs Standard Therapy in Treatment-Resistant Metastatic NSCLC
1. The median OS was 13.2 months with TTFields arm vs 9.9 months with standard arm, with an HR of ...
Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy
1. The objective response rate was 29.8% (1% complete response, 66% partial response) with a PFS of 5.5 months and ...
#VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer
1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
